Anti-S28A3/ SLC28A3/ CNT3 monoclonal antibody

Anti-S28A3/ SLC28A3/ CNT3 antibody for FACS & in-vivo assay

Target products collectionGo to SLC28A3/SLC28A3 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-MP1585-Ab-1/ GM-Tg-hg-MP1585-Ab-2Anti-Human SLC28A3 monoclonal antibodyHuman
GM-Tg-rg-MP1585-Ab-1/ GM-Tg-rg-MP1585-Ab-2Anti-Rat SLC28A3 monoclonal antibodyRat
GM-Tg-mg-MP1585-Ab-1/ GM-Tg-mg-MP1585-Ab-2Anti-Mouse SLC28A3 monoclonal antibodyMouse
GM-Tg-cynog-MP1585-Ab-1/ GM-Tg-cynog-MP1585-Ab-2Anti-Cynomolgus/ Rhesus macaque SLC28A3 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-MP1585-Ab-1/ GM-Tg-felg-MP1585-Ab-2Anti-Feline SLC28A3 monoclonal antibodyFeline
GM-Tg-cang-MP1585-Ab-1/ GM-Tg-cang-MP1585-Ab-2Anti-Canine SLC28A3 monoclonal antibodyCanine
GM-Tg-bovg-MP1585-Ab-1/ GM-Tg-bovg-MP1585-Ab-2Anti-Bovine SLC28A3 monoclonal antibodyBovine
GM-Tg-equg-MP1585-Ab-1/ GM-Tg-equg-MP1585-Ab-2Anti-Equine SLC28A3 monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-MP1585-Ab-1/ GM-Tg-hg-MP1585-Ab-2; GM-Tg-rg-MP1585-Ab-1/ GM-Tg-rg-MP1585-Ab-2;
GM-Tg-mg-MP1585-Ab-1/ GM-Tg-mg-MP1585-Ab-2; GM-Tg-cynog-MP1585-Ab-1/ GM-Tg-cynog-MP1585-Ab-2;
GM-Tg-felg-MP1585-Ab-1/ GM-Tg-felg-MP1585-Ab-2; GM-Tg-cang-MP1585-Ab-1/ GM-Tg-cang-MP1585-Ab-2;
GM-Tg-bovg-MP1585-Ab-1/ GM-Tg-bovg-MP1585-Ab-2; GM-Tg-equg-MP1585-Ab-1/ GM-Tg-equg-MP1585-Ab-2
Products NameAnti-SLC28A3 monoclonal antibody
Formatmab
Target NameSLC28A3
Protein Sub-locationTransmembrane Protein
Category of antibodyFACS/Biofunctional Antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-SLC28A3 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenProducts DevelopingMulti-species S28A3/ SLC28A3/ CNT3 VLP (virus-like particle) (Products Developing)


    Target information

    Target IDGM-MP1585
    Target NameSLC28A3
    Gene ID64078,114304,140944,709560,119870820,101082270,508028
    Gene Symbol and SynonymsCNT3,SLC28A3
    Uniprot AccessionQ9HAS3,Q8VIH3
    Uniprot Entry NameS28A3_HUMAN,S28A3_RAT
    Protein Sub-locationTransmembrane Protein
    Category
    DiseaseN/A
    Gene EnsemblENSG00000197506
    Target ClassificationN/A

    The target: SLC28A3, gene name: SLC28A3, also named as CNT3. Nucleoside transporters, such as SLC28A3, regulate multiple cellular processes, including neurotransmission, vascular tone, adenosine concentration in the vicinity of cell surface receptors, and transport and metabolism of nucleoside drugs. SLC28A3 shows broad specificity for pyrimidine and purine nucleosides (Ritzel et al., 2001 [PubMed 11032837]).[supplied by OMIM, Mar 2008].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.